News
-
-
PRESS RELEASE
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Inventiva announces availability of preparatory documents for Combined General Meeting on December 11, 2024. Shareholders can participate in person or request documents electronically. Detailed resolutions and meeting information provided -
PRESS RELEASE
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
Inventiva reports total voting rights and shares as of November 4, 2024, in accordance with Article R. 22-10-23 of the French Commercial Code. The company is a clinical-stage biopharmaceutical with a focus on oral small molecule therapies -
-
PRESS RELEASE
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva presents positive results from Phase 2 study on lanifibranor and empagliflozin combination therapy for MASH and T2D patients at AASLD The Liver Meeting® 2024 -
-
-
-
-
